Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 458.12 USD -1.55% Market Closed
Market Cap: 60.5B USD

Profitability Summary

Alnylam Pharmaceuticals Inc's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Alnylam Pharmaceuticals Inc

Revenue
2.5B USD
Cost of Revenue
-402.7m USD
Gross Profit
2.1B USD
Operating Expenses
-2.2B USD
Operating Income
-180.2m USD
Other Expenses
-138.9m USD
Net Income
-319.1m USD

Margins Comparison
Alnylam Pharmaceuticals Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.8B USD
84%
-7%
-13%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
399.6B USD
71%
33%
4%
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
72%
34%
19%
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD
79%
39%
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD
86%
39%
31%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.1B USD
86%
28%
32%
AU
CSL Ltd
ASX:CSL
89.1B AUD
52%
26%
19%
NL
argenx SE
XBRU:ARGX
46.9B EUR
90%
22%
43%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Alnylam Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.8B USD
-258%
-7%
-6%
-10%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
399.6B USD
139%
2%
20%
28%
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
82%
8%
17%
15%
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD
41%
14%
25%
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD
22%
16%
23%
25%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.1B USD
15%
12%
11%
12%
AU
CSL Ltd
ASX:CSL
89.1B AUD
16%
8%
12%
10%
NL
argenx SE
XBRU:ARGX
46.9B EUR
30%
26%
15%
61%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less